The oncogene-enriched subtype was characterised by overexpression of genes associated with cancer progression including ERBB2, SLC44A4, and EPCAM, whereas the immune-enriched subtype was marked by overexpression of genes with roles in immune pathways including IL23A, TRA, and CD37. The mixed subtype was characterised by overexpression of genes from both categories. This evidence concerns the gene CD37 and cancer.